Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel
Open Access
- 17 July 2013
- journal article
- research article
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 21 (1) , 58
Abstract
Background: Poly lactic-co-glycolic acid (PLGA) based nanoparticles are considered to be a promising drug carrier in tumor targeting but suffer from the high level of opsonization by reticuloendothelial system due to their hydrophobic structure. As a result surface modification of these nanoparticles has been widely studied as an essential step in their development. Among various surface modifications, human serum albumin (HSA) possesses advantages including small size, hydrophilic surface and accumulation in leaky vasculature of tumors through passive targeting and a probable active transport into tumor tissues. Methods: PLGA nanoparticles of docetaxel were prepared by emulsification evaporation method and were surface conjugated with human serum albumin. Fourier transform infrared spectrum was used to confirm the conjugation reaction where nuclear magnetic resonance was utilized for conjugation ratio determination. In addition, transmission electron microscopy showed two different contrast media in conjugated nanoparticles. Furthermore, cytotoxicity of free docetaxel, unconjugated and conjugated PLGA nanoparticles was studied in HepG2 cells. Results: Size, zeta potential and drug loading of PLGA nanoparticles were about 199 nm, −11.07 mV, and 4%, respectively where size, zeta potential and drug loading of conjugated nanoparticles were found to be 204 nm, −5.6 mV and 3.6% respectively. Conjugated nanoparticles represented a three-phasic release pattern with a 20% burst effect for docetaxel on the first day. Cytotoxicity experiment showed that the IC50 of HSA conjugated PLGA nanoparticles (5.4 μg) was significantly lower than both free docetaxel (20.2 μg) and unconjugated PLGA nanoparticles (6.2 μg). Conclusion: In conclusion surface modification of PLGA nanoparticles through HSA conjugation results in more cytotoxicity against tumor cell lines compared with free docetaxel and unconjugated PLGA nanoparticles. Albumin conjugated PLGA nanoparticles may represent a promising drug delivery system in cancer therapy.Keywords
This publication has 33 references indexed in Scilit:
- PLGA-based nanoparticles: An overview of biomedical applicationsJournal of Controlled Release, 2012
- Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugatesJournal of Controlled Release, 2011
- Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agentsInternational Journal of Nanomedicine, 2011
- Nanoparticles of Conjugated Methotrexate-Human Serum Albumin: Preparation and Cytotoxicity EvaluationsJournal of Nanomaterials, 2010
- The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targetingJournal of Controlled Release, 2010
- Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic®P85, anin vitrocell line andin vivobiodistribution studies on rat modelJournal of Drug Targeting, 2009
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- Paclitaxel-loaded PLGA nanoparticles: Potentiation of anticancer activity by surface conjugation with wheat germ agglutininJournal of Controlled Release, 2005
- Enhanced Antiproliferative Activity of Transferrin-Conjugated Paclitaxel-Loaded Nanoparticles Is Mediated via Sustained Intracellular Drug RetentionMolecular Pharmaceutics, 2005
- Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJournal of Controlled Release, 2000